-+ 0.00%
-+ 0.00%
-+ 0.00%

Lixte Biotechnology Holdings Inc. Outlines Strategy to Expand Oncology Platform with Complementary Modalities, Advancing PP2A Inhibitor Development and Integrating Radiotherapy Technologies

Reuters·12/08/2025 13:30:52

Please log in to view news